Some have hypothesized that the use of angiotensin-converting enzyme inhibitors 
(ACEI) and angiotensin-receptor blockers (ARB) may modify susceptibility to 
coronavirus disease-2019 (COVID-19) in humans. Thus, we conducted two 
meta-analyses to investigate the effect of ACEI and ARB on mortality and 
susceptibility to COVID-19. Pubmed and EMBASE were searched through June 2020 to 
identify clinical trials that investigated the testing positive and in-hospital 
mortality rates for COVID-19 for those who were treated with ACEI and/or ARB and 
for those who were not treated with ACEI or ARB. The first analysis investigated 
the testing positive rate of COVID-19. The second analysis investigated the 
in-hospital mortality rate for patients with COVID-19. Three eligible studies 
for the first analysis and 14 eligible studies for the second analysis were 
identified. The first analysis demonstrated that the use of ACEI or ARB did not 
affect the testing positive rates (odds ratio [OR] [confidence interval 
[CI]] = 0.96 [0.88-1.04]; p = .69, OR [CI] = 0.99 [0.91-1.08]; p = 0.35, 
respectively). The second analysis showed that the use of ACEI and/or ARB did 
not affect in-hospital mortality (risk ratio [RR] 95% [CI]] = 0.88 [0.64-1.20], 
p = 0.42). The subgroup analysis by limiting studies of patients with 
hypertension showed ACEI and/or ARB use was associated with a significant 
reduction of in-hospital mortality compared with no ACEI or ARB use (RR 
[CI] = 0.66 [0.49-0.89], p = 0.004). Our analysis demonstrated that ACEI and/or 
ARB use was associated neither with testing positive rates of COVID-19 nor with 
mortality of COVID-19 patients.